Kathleen A. Dorritie
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)

Dr. Kathleen A. Dorritie

Hematology Oncology
5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
On Staff At
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Offers Telehealth
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kathleen Dorritie, MD, is a hematologist/medical oncologist at UPMC Hillman Cancer Center specializing in hematologic malignancies and stem cell transplantation. Her research focuses on early phase clinical trials for lymphoid malignancies. She has been very involved in the development of the CAR T-cell program at UPMC and has also worked to develop a stem cell transplant program for hemoglobinopathies, including sickle cell disease.

Dr. Dorritie is rated as an Advanced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 38 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 2 clinical trials in the study of Diffuse Large B-Cell Lymphoma (DLBCL).

Graduate Institution
SUNY Upstate Medical University
Residency
University of Pittsburgh School of Medicine
Specialties
Hematology Oncology
Licenses
Internal Medicine in PA
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
University of Pittsburgh School of Medicine
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, Pittsburgh, PA 15232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Mesna, Methotrexate, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Study Phase: Phase 3
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)
Enrollment Status: Recruiting
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drug: Belantamab
Study Phase: Phase 1
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Biological, Procedure
Study Drugs: Blinatumomab, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drug: Belantamab Mafodotin
Study Phase: Phase 1
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug, Biological
Study Drugs: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
A Phase 1/2 Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.
A Phase 1/2 Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Betalutin
Study Phase: Phase 1/Phase 2
Phase 2 Trial of the Heat Shock Protein-90 (Hsp90) Inhibitor AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ ALCL, Mantle Cell Lymphoma, and BCL6+ DLBCL
Phase 2 Trial of the Heat Shock Protein-90 (Hsp90) Inhibitor AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ ALCL, Mantle Cell Lymphoma, and BCL6+ DLBCL
Enrollment Status: Terminated
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drug: Onalespib
Study Phase: Phase 2
A Pilot Study Evaluating the Efficacy of Non-Myeloablative Matched Related Donor Peripheral Blood Stem Cell Transplant in Patients With Severe Sickle Cell Disease
A Pilot Study Evaluating the Efficacy of Non-Myeloablative Matched Related Donor Peripheral Blood Stem Cell Transplant in Patients With Severe Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: June 28, 2022
Intervention Type: Drug, Radiation
Study Drugs: Alemtuzumab, Sirolimus
Study Phase: Early Phase 1
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Enrollment Status: Completed
Publish Date: October 15, 2019
Intervention Type: Drug, Other, Radiation
Study Phase: Phase 1
View 10 Less Clinical Trials

38 Total Publications

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 02, 2024
Similar Doctors
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Cyrus M. Khan
Hematology Oncology | Hematology | Oncology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Cyrus M. Khan
Hematology Oncology | Hematology | Oncology

Allegheny Clinic

4800 Friendship Ave, 
Pittsburgh, PA 
 (0.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Cyrus Khan is a Hematologist Oncology specialist and a Hematologist in Pittsburgh, Pennsylvania. Dr. Khan is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed Refractory Multiple Myeloma (RRMM), Chronic B-Cell Leukemia (CBCL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Lauren W. Veltri
Hematology Oncology | Hematology | Oncology
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Lauren W. Veltri
Hematology Oncology | Hematology | Oncology

West Virginia University Medical Corporation

Medical Ctr Dr, 
Morgantown, WV 
 (55.5 miles away)
304-598-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lauren Veltri is a Hematologist Oncology specialist and a Hematologist in Morgantown, West Virginia. Dr. Veltri is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Vitrectomy. Dr. Veltri is currently accepting new patients.

Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. John W. Lister
Hematology Oncology | Oncology | Hematology
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. John W. Lister
Hematology Oncology | Oncology | Hematology

Allegheny Clinic

4815 Liberty Ave, 
Pittsburgh, PA 
 (0.5 miles away)
412-578-4484
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Lister is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Lister is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dorritie's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile